Praxis Precision Medicines reported that its oral candidate ulixacaltamide met primary and key secondary endpoints across two Phase 3 trials for essential tremor, with the company preparing a planned NDA submission in early 2026. Trial data showed clinically meaningful improvements in activities‑of‑daily‑living scores and maintenance of effect in a randomized‑withdrawal design, addressing a condition with substantial unmet need. Investors reacted strongly: Praxis shares vaulted on the readout and management signaled intent to proceed with regulatory interactions. The trials enrolled hundreds of patients and included diverse endpoints and a randomized‑withdrawal phase intended to demonstrate durability of response and tolerability in a real‑world‑like setting. Clarification: essential tremor is a common movement disorder causing involuntary rhythmic shaking that currently lacks FDA‑approved first‑line therapies providing broad symptomatic relief.